This post was originally published on this site
AstraZeneca PLC said Monday that it will discontinue the trial for the drug Epanova following a recommendation from an independent data-monitoring committee.
The company AZN, -0.46% AZN, -0.47% said it has decided to close the phase three trial for the drug due to its low likelihood of demonstrating a benefit to patients with mixed dyslipidaemia who are at risk of cardiovascular disease.
“We are disappointed by these results, but we remain committed to addressing the needs of patients in the cardiovascular space where we have an extensive pipeline,” Executive Vice President of BioPharmaceuticals R&D Mene Pangalos said.
